Atlas Venture funds (KYMR) report 3.4% beneficial stake in Kymera Therapeutics

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. has updated institutional ownership details in an amended Schedule 13G. A group of affiliated Atlas Venture funds collectively report 2,847,541 shares of Kymera common stock, representing 3.4% of outstanding shares based on 83,150,618 shares outstanding as of July 31, 2026. The Fund X entities each have shared voting and dispositive power over 2,384,685 shares, while the Opportunity Fund entities each have shared voting and dispositive power over 462,856 shares. None of the reporting entities has sole voting or dispositive power, and they state that they may be deemed a group but expressly disclaim group status under Section 13.

Key Figures

Fund X shares owned: 2,384,685 shares Opportunity Fund shares owned: 462,856 shares Total shares beneficially owned: 2,847,541 shares +4 more

7 metrics

Fund X shares owned 2,384,685 shares Common stock beneficially owned by Atlas Venture Fund X and related entities

Opportunity Fund shares owned 462,856 shares Common stock beneficially owned by Atlas Venture Opportunity Fund I and related entities

Total shares beneficially owned 2,847,541 shares Aggregate Kymera common stock reported by all Atlas Venture reporting persons

Fund X ownership percentage 2.9% Percent of Kymera common stock class attributed to Fund X reporting persons

Opportunity Fund ownership percentage 0.6% Percent of Kymera common stock class attributed to Opportunity Fund reporting persons

Total ownership percentage 3.4% Aggregate percent of Kymera outstanding common stock beneficially owned

Shares outstanding 83,150,618 shares Kymera common shares outstanding as of July 31, 2026, per Form 10-Q

Key Terms

beneficially own, shared voting power, dispositive power, Schedule 13G, +1 more

5 terms

beneficially own financial

"Collectively, the Reporting Persons beneficially own an aggregate of 2,847,541 shares"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

shared voting power financial

"Each Fund X Reporting Person shares power to vote or direct the vote of 2,384,685 shares"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

dispositive power financial

"shares power to dispose or to direct the disposition of 2,384,685 shares of Common Stock"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"This is filed by (i) Atlas Venture Fund X, L.P. ... the "Reporting Persons")"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Section 13 regulatory

"shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13"

Section 13 of the U.S. Securities Exchange Act requires public companies and large shareholders to disclose important ownership and reporting information to the market, including regular financial reports and filings when someone builds a significant stake. For investors it acts like a public checkbook and alert system: it provides verified updates on a company’s health and who controls it, helping buyers judge risk, spot takeover activity, and make informed decisions.

FAQ

How many Kymera Therapeutics (KYMR) shares do the Atlas Venture funds report owning?

The Atlas Venture reporting entities collectively report 2,847,541 shares of Kymera Therapeutics common stock. This total combines 2,384,685 shares held by Atlas Venture Fund X and 462,856 shares held by Atlas Venture Opportunity Fund I.

What percentage of Kymera Therapeutics (KYMR) does Atlas Venture beneficially own?

The filing states the Atlas Venture reporting persons beneficially own 3.4% of Kymera’s outstanding common stock. This is based on 83,150,618 shares outstanding as of July 31, 2026, as reported in Kymera’s Form 10-Q.

How is ownership split between Atlas Venture Fund X and the Opportunity Fund in KYMR?

Atlas Venture Fund X and its affiliates report 2,384,685 Kymera shares, or 2.9% of the class. Atlas Venture Opportunity Fund I and its affiliates report 462,856 shares, or 0.6% of the class, all as common stock.

Do the Atlas Venture entities have sole or shared voting power over Kymera (KYMR) shares?

The filing states the Atlas Venture entities have no sole voting power over Kymera shares. Each Fund X reporting person shares voting and dispositive power over 2,384,685 shares, and each Opportunity Fund reporting person shares such power over 462,856 shares.

Are the Atlas Venture entities considered a group under Section 13 for KYMR?

The filing notes the Fund X and Opportunity Fund reporting persons are under common control and may be deemed a group. However, they expressly disclaim group membership, stating this should not be viewed as an admission for Section 13 or other purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 04:43 PM Accepted by SEC EDGAR 08/13/2026 - 04:42 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

Kymera Therapeutics, Inc.

(Name of Issuer)

COMMON STOCK, $0.0001 PAR VALUE

(Title of Class of Securities)

501575104

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 501575104

1

Names of Reporting Persons

Atlas Venture Fund X, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,384,685.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,384,685.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,384,685.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.9 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 501575104

1

Names of Reporting Persons

ATLAS VENTURE ASSOCIATES X, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,384,685.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,384,685.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,384,685.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.9 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 501575104

1

Names of Reporting Persons

Atlas Venture Associates X, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,384,685.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,384,685.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,384,685.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 501575104

1

Names of Reporting Persons

Atlas Venture Opportunity Fund I, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 462,856.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 462,856.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

462,856.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.6 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 501575104

1

Names of Reporting Persons

Atlas Venture Associates Opportunity I, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 462,856.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 462,856.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

462,856.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.6 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 501575104

1

Names of Reporting Persons

Atlas Venture Associates Opportunity I, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 462,856.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 462,856.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

462,856.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.6 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Kymera Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 500 North Beacon Street, 4th Floor, WATERTOWN, MA, 02472.
Item 2.
(a)	Name of person filing: This Schedule 13G is filed by (i) Atlas Venture Fund X, L.P., a Delaware limited partnership ("Atlas X"), (ii) Atlas Venture Associates X, L.P., a Delaware limited partnership ("AVA X LP"), (iii) Atlas Venture Associates X, LLC, a Delaware limited liability company ("AVA X LLC" and together with Atlas X and AVA X LP, the "Fund X Reporting Persons"), (iv) Atlas Venture Opportunity Fund I, L.P., a Delaware limited partnership ("AVO I"), (v) Atlas Venture Associates Opportunity I, L.P., a Delaware limited partnership ("AVAO LP") and (vi) Atlas Venture Associates Opportunity I, LLC, a Delaware limited liability company ("AVAO LLC" and together with AVO I and AVAO LP, the "Opportunity Fund Reporting Persons" and together with the Fund X Reporting Persons, the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: 300 Technology Square, 8th Floor Cambridge, Massachusetts 02139
(c)	Citizenship: Each of Atlas X, AVA X LP, AVO I and AVAO LP is a Delaware limited partnership. Each of AVA X LLC and AVAO LLC is a Delaware limited liability company.
(d)	Title of class of securities: COMMON STOCK, $0.0001 PAR VALUE
(e)	CUSIP No.: 501575104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Atlas X is the record owner of 2,384,685 shares of Common Stock. AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of Atlas X, AVA X LP and AVA X LLC has shared voting and dispositive power over the shares held by Atlas X. As such, each of Atlas X, AVA X LP and AVA X LLC may be deemed to beneficially own the shares held by Atlas X. AVO I is the record owner of 462,856 shares of Common Stock. AVAO LP is the general partner of AVO I and AVAO LLC is the general partner of AVAO LP. Each of AVO I, AVAO LP and AVAO LLC has shared voting and dispositive power over the shares held by AVO I. As such, each of AVO I, AVAO LP and AVAO LLC may be deemed to beneficially own the shares held by AVO I.
(b)	Percent of class: Fund X Reporting Persons and Opportunity Fund Reporting Persons may be deemed to beneficially own 2.9% and 0.6%, respectively, of the Issuer's outstanding Common Stock, which percentages are calculated based upon 83,150,618 outstanding shares of Common Stock of the Issuer as of July 31, 2026, as reported in the Issuer's 10-Q, filed with the Securities and Exchange Commission on August 5, 2026. Collectively, the Reporting Persons beneficially own an aggregate of 2,847,541 shares of Common Stock, which represents 3.4% of the Issuer's outstanding Common Stock. The Fund X Reporting Persons and the Opportunity Fund Reporting Persons are under common control and as a result, the Reporting Persons may be deemed to be members of a group. However, the Reporting Persons disclaim such group membership, and this Schedule 13G shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13 or for any other purposes.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: None of the Reporting Persons have the sole power to direct the vote of the Common Stock.
	(ii) Shared power to vote or to direct the vote: Each Fund X Reporting Person shares power to vote or direct the vote of 2,384,685 shares of Common Stock and each Opportunity Fund Reporting Person shares power to vote or direct the vote of 462,856 shares of Common Stock.
	(iii) Sole power to dispose or to direct the disposition of: Sole power to dispose or to direct the disposition of: None of the Reporting Persons have the sole power to dispose or to direct the disposition of the Common Stock.
	(iv) Shared power to dispose or to direct the disposition of: Each Fund X Reporting Person shares power to dispose or to direct the disposition of 2,384,685 shares of Common Stock and each Opportunity Fund Reporting Person shares power to dispose or to direct the disposition of 462,856 shares of Common Stock.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Atlas Venture Fund X, L.P.

Signature:	/s/ Ommer Chohan
Name/Title:	By: Atlas Venture Associates X, L.P., its GP, By: Atlas Venture Associates X, LLC, its GP, By: Ommer Chohan, CFO
Date:	08/13/2026

ATLAS VENTURE ASSOCIATES X, L.P.

Signature:	/s/ Ommer Chohan
Name/Title:	By: Atlas Venture Associates X, LLC, its GP, By: Ommer Chohan, CFO
Date:	08/13/2026

Atlas Venture Associates X, LLC

Signature:	/s/ Ommer Chohan
Name/Title:	Ommer Chohan, CFO
Date:	08/13/2026

Atlas Venture Opportunity Fund I, L.P.

Signature:	/s/ Ommer Chohan
Name/Title:	By: Atlas Venture Associates Opportunity I, L.P., its GP, By: Atlas Venture Associates Opportunity I, LLC, its GP, By: Ommer Chohan, CFO
Date:	08/13/2026

Atlas Venture Associates Opportunity I, L.P.

Signature:	/s/ Ommer Chohan
Name/Title:	By: Atlas Venture Associates Opportunity I, LLC, its GP, By: Ommer Chohan, CFO
Date:	08/13/2026

Atlas Venture Associates Opportunity I, LLC

Signature:	/s/ Ommer Chohan
Name/Title:	Ommer Chohan, CFO
Date:	08/13/2026

Exhibit Information

99.1 Joint Filing Agreement (Incorporated by reference to Exhibit A to the Schedule 13G/A, filed with the Securities and Exchange Commission on February 14, 2023)